Form 4 for AARD Aardvark Therapeutics, Inc.

Accepted 2025-02-19 00:00:00 ET · period of report 2025-02-14 · accession 0000950170-25-023243 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-02-19	2025-02-14	AARD	Sun Nelson	CFO	P - Purchase	$16.00	+10.0K	99.5K	+11%	+$160.0K
D	2025-02-19	2025-02-14	AARD	Sun Nelson	CFO	C - Cnv Deriv	—	+7,001	89.5K	+8%	—
D	2025-02-19	2025-02-14	AARD	Sun Nelson	CFO	C - Cnv Deriv	$0.00	-59.3K	0	-100%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-02-14	P	A	10,000	$16.00	99,484	D	—	—
2	Common	Common Stock	2025-02-14	C	A	7,001	—	89,484	D	—	—	(F1) The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date.
3	Derivative	Series C Convertible Preferred Stock	2025-02-14	C	D	59,332	$0.00	0	D	— · — to —	7,001 Common Stock	(F1) The Series C Convertible Preferred Stock of Aardvark Therapeutics, Inc. (the "Issuer") automatically converted on an 8.474-for-1 basis into shares of the Issuer's common stock ("Common Stock") immediately prior to the closing of the Issuer's initial public offering of its Common Stock. The Series C Convertible Preferred Stock had no expiration date.